The Washington Post put it well in March 2026: "The miracle of rapid weight loss has always come with fine print." Until recently, that fine print was mostly a list of digestive complaints
Newly diagnosed diabetes mellitus after acute pancreatitis: a systematic review and meta-analysis
The Primary Allegations Plaintiffs in the GLP-1 MDL allege: Failure to warn consumers and doctors about the risks of gastroparesis and intestinal obstruction Design defects in the medications Inadequate post-market surveillance and reaction to adverse events Negligent marketing practices that downplayed serious side effects These claims are supported by growing adverse event reports and emerging studies linking GLP-1 medications to prolonged and debilitating digestive disorders
Any change in size, color, shape, or surface texture over weeks or months is the single most important warning sign
Local and International Deals 10 MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES 10.1
Our experienced team provides personalized guidance, monitors side effects, reviews your progress, and helps you make informed decisions throughout treatment
